CL2013002085A1 - Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion. - Google Patents

Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion.

Info

Publication number
CL2013002085A1
CL2013002085A1 CL2013002085A CL2013002085A CL2013002085A1 CL 2013002085 A1 CL2013002085 A1 CL 2013002085A1 CL 2013002085 A CL2013002085 A CL 2013002085A CL 2013002085 A CL2013002085 A CL 2013002085A CL 2013002085 A1 CL2013002085 A1 CL 2013002085A1
Authority
CL
Chile
Prior art keywords
circulating
levels
glucose
compounds
procedure
Prior art date
Application number
CL2013002085A
Other languages
English (en)
Inventor
Keld Fosgerau
Ditte Riber
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2013002085A1 publication Critical patent/CL2013002085A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2013002085A 2011-01-20 2013-07-19 Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion. CL2013002085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161434698P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
CL2013002085A1 true CL2013002085A1 (es) 2013-12-06

Family

ID=45607302

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002085A CL2013002085A1 (es) 2011-01-20 2013-07-19 Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion.

Country Status (20)

Country Link
US (2) US20140011733A1 (es)
EP (1) EP2665487A1 (es)
JP (1) JP2014504597A (es)
KR (1) KR20140043709A (es)
CN (1) CN103491975B (es)
AR (1) AR085086A1 (es)
AU (1) AU2012208349A1 (es)
BR (1) BR112013018269A2 (es)
CA (1) CA2824397A1 (es)
CL (1) CL2013002085A1 (es)
CO (1) CO6761400A2 (es)
EA (1) EA201390796A1 (es)
MA (1) MA34913B1 (es)
MX (1) MX2013008005A (es)
PE (1) PE20140969A1 (es)
SG (1) SG192038A1 (es)
TN (1) TN2013000251A1 (es)
TW (1) TW201247702A (es)
UY (1) UY33872A (es)
WO (1) WO2012098462A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2502218T3 (es) 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
CA2767792A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
TR201815338T4 (tr) 2012-05-03 2018-11-21 Zealand Pharma As Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2970511B1 (en) * 2013-03-14 2020-09-30 Indiana University Research and Technology Corporation Insulin-incretin conjugates
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
DK3057984T3 (en) 2013-10-17 2018-10-08 Zealand Pharma As ACYLED GLUCAGON ANALOGS
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
JP2017505141A (ja) 2014-01-20 2017-02-16 ハンミ ファーマシューティカル カンパニー リミテッド 長時間作用型インスリンおよびその使用
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CA2980978A1 (en) * 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
EP3430033A4 (en) * 2016-03-18 2019-11-20 Merck Sharp & Dohme Corp. CONJUGATES OF INSULIN-INCRETIN
US11058775B2 (en) 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
TWI798209B (zh) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
AU2019405389A1 (en) * 2018-12-21 2021-06-24 Hanmi Pharm. Co., Ltd. Pharmaceutical composition containing insulin and glucagon
CA3186427A1 (en) * 2020-06-11 2021-12-16 Abvance Therapeutics Inc. Systems, devices, compositions and methods for treating diabetes
AU2022392980A1 (en) * 2021-11-19 2024-07-04 Medshine Discovery Inc. Stapled peptide and use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
UA45321C2 (uk) 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
PT929567E (pt) 1996-09-09 2005-07-29 Zealand Pharma As Sintese em fase solida de peptidos
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
IL161848A0 (en) 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1620465A2 (en) 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
PT1891105E (pt) 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CN102065885A (zh) 2008-04-22 2011-05-18 卡斯西部储备大学 同种型特异性的胰岛素类似物
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN103641907A (zh) * 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
EP2318432B1 (en) 2008-07-31 2015-09-02 Case Western Reserve University Halogen-stabilized insulin
JP5635531B2 (ja) * 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2502218T3 (es) * 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
UA104605C2 (uk) * 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
WO2010070252A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
CA2767792A1 (en) * 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
SG192038A1 (en) 2013-08-30
EA201390796A1 (ru) 2014-07-30
TW201247702A (en) 2012-12-01
BR112013018269A2 (pt) 2017-06-06
TN2013000251A1 (en) 2014-11-10
CO6761400A2 (es) 2013-09-30
KR20140043709A (ko) 2014-04-10
US20140011733A1 (en) 2014-01-09
US20160000883A1 (en) 2016-01-07
MA34913B1 (fr) 2014-02-01
AR085086A1 (es) 2013-09-11
CA2824397A1 (en) 2012-07-26
WO2012098462A1 (en) 2012-07-26
CN103491975A (zh) 2014-01-01
MX2013008005A (es) 2013-08-21
PE20140969A1 (es) 2014-07-24
UY33872A (es) 2012-08-31
AU2012208349A1 (en) 2013-07-18
CN103491975B (zh) 2016-05-11
EP2665487A1 (en) 2013-11-27
JP2014504597A (ja) 2014-02-24
NZ612719A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
CL2013002085A1 (es) Combinacion de compuestos para su uso en un procedimiento para prevenir o reducir el aumento de peso, estimular la perdida de peso, mejorar los niveles de glucosa en circulación, la tolerancia a la glucosa o los niveles de colesterol en circulacion.
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
SMT201600155B (it) Pirazolo[i, 5-a]pirimidine e -triazine come agenti antivirali
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112014015535A2 (pt) uso de compostos de fórmula i, método para combater fungos fitopatogênicos e composições agroquímicas
DK2736797T3 (da) Foldemekanisme med spærring
DK2661243T3 (da) Konstruktioner, opnåede ved vævsteknologi
CL2013003487A1 (es) Uso de un compuesto derivado de fosforamidato de nucleosido para tratar la fiebre dengue y compuestos especificos.
CO6970598A2 (es) Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares
BR112013020608A2 (pt) simulador para formação de equipe, particularmente, para formação de tripulação de helicóptero
BR112014013213A2 (pt) composição microbicida, método para fornecer um efeito bactericida a um substrato e uso de uma composição
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
CL2014003565A1 (es) Uso de 2-metileno-19-nor-(20s)-1alpha,25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
CL2013002823A1 (es) Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
CL2013002026A1 (es) Compuesto solido (r)-1-etil-3-[5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]-urea y metodo para prepararla.
CO6801728A2 (es) Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis
BR112013031562A2 (pt) combinação parasiticida, composição parasiticida, método para o combate de insetos parasíticos e de acarídeos em um animal, kit, e, uso de uma combinação.
BR112013010274A2 (pt) composição de emulsão para uso como potencializador em uma formulação herbicida líquida solúvel, método para preparar uma composição de emulsão, formulação herbicida líquida solúvel, método para melhorar o desempenho da formulação herbicida líquida solúvel e uso de uma composição de emulsão
BR112013016244A2 (pt) microvesículas cheias de gás para uso como vacinas.
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
BRPI1016081A2 (pt) composição e método e composto para tratar degeneração macular, bem como uso de um composto 15-ceto prostaglandina
CO7071125A2 (es) Composiciones, síntesis y métodos para el uso de derivados de fenilcicloalquilmetilamino
ES1076086Y (es) Conjunto de seguridad para cerraduras
ES1075233Y (es) Soporte para laminados fotovoltaicos